Search Results - "Pieńkowski, T."

Trastuzumab treatment in patients with breast cancer and metastatic CNS disease by Pieńkowski, T., Zielinski, C.C.

“…Background: Patients with metastatic central nervous system (mCNS) disease progression from breast cancer have a poor prognosis and often develop associated…”
Get full text

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial by Mackey, J.R., Pieńkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M.F., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., Eiermann, W.

“…The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide…”
Get full text

Survival of HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine: A national population-based study: Long-term analysis by Jagielska, B., Tokajuk, P., Pieńkowski, T., Czubek, A., Krzakowski, M.J., Wojtukiewicz, M.Z.

Get full text

Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies by Bianchini, G., Parker, J., Carey, L., Perou, C.M., Sica, L., Prat, A., Pieńkowski, T., Im, Y.-H., Bianchi, G.V., Ling-Ming, T., Liu, M.-C., Lluch, A., Semiglazov, V., de la Haba-Rodriguez, J., Oh, D.-Y., Poirier, B., Pedrini, J.L., Valagussa, P., Gianni, L.

Get full text

Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial by JASSEM, Jacek, PIENKOWSKI, Tadeusz, MUNIER, Stephane, WEIL, Catherine, PŁUZANSKA, Anna, JELIC, Svetislav, GORBUNOVA, Vera, MRSIC-KRMPOTIC, Zrinka, BERZINS, Juris, NAGYKALNAI, Tomas, WIGLER, Nelly, RENARD, Josette

“…This phase III trial compared the efficacy and safety of doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) as…”
Get full text

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial by Bianchini, G., Pusztai, L., Pienkowski, T., Im, Y.-H., Bianchi, G.V., Tseng, L.-M., Liu, M.-C., Lluch, A., Galeota, E., Magazzù, D., de la Haba-Rodríguez, J., Oh, D.-Y., Poirier, B., Pedrini, J.L., Semiglazov, V., Valagussa, P., Gianni, L.

“…To investigate in the NeoSphere trial the contribution of the immune system to pathologic complete response in the breast (pCRB) after neoadjuvant docetaxel…”
Get full text

A global meta-analysis of the economic values of provisioning and cultural ecosystem services by Teoh, S.H.S., Symes, W.S., Sun, H., Pienkowski, T., Carrasco, L.R.

“…Despite a growing demand to integrate ecosystem services into sustainability decision-making, our understanding of the global distribution of the economic…”
Get full text

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer by Pegram, Mark D., Pienkowski, Tadeusz, Northfelt, Donald W., Eiermann, Wolfgang, Patel, Ravi, Fumoleau, Pierre, Quan, Eleonor, Crown, John, Toppmeyer, Deborah, Smylie, Michael, Riva, Alessandro, Blitz, Sandra, Press, Michael F., Reese, David, Lindsay, Mary-Ann, Slamon, Dennis J.

“…Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody…”
Get full text

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial by Rabaglio, M., Sun, Z., Price, K.N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J.F., Paridaens, R.J., Colleoni, M., Pienkowski, T., Nogaret, J.-M., Láng, I., Smith, I., Gelber, R.D., Goldhirsch, A., Coates, A.S.

“…To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive…”
Get full text

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients by Smith, I.E., Pierga, J.-Y., Biganzoli, L., Cortés-Funes, H., Thomssen, C., Pivot, X., Fabi, A., Xu, B., Stroyakovskiy, D., Franke, F.A., Kaufman, B., Mainwaring, P., Pienkowski, T., De Valk, B., Kwong, A., González-Trujillo, J.L., Koza, I., Petrakova, K., Pereira, D., Pritchard, K.I.

“…First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2…”
Get full text

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses by Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, Zielinski, C

“…Background: The randomised phase III TURANDOT trial compared first-line bevacizumab–paclitaxel (BEV–PAC) vs bevacizumab–capecitabine (BEV–CAP) in HER2-negative…”
Get full text

ONCOPOOL – A European database for 16,944 cases of breast cancer by Blamey, R.W, Hornmark-Stenstam, B, Ball, G, Blichert-Toft, M, Cataliotti, L, Fourquet, A, Gee, J, Holli, K, Jakesz, R, Kerin, M, Mansel, R, Nicholson, R, Pienkowski, T, Pinder, S, Sundquist, M, van de Vijver, M, Ellis, I

“…Abstract ONCOPOOL is a retrospectively compiled database of primary operable invasive breast cancers treated in the 1990s in 10 European breast cancer Units…”
Get full text

E08. Highlights in benign and pre-invasive breast disease by Mundinger, A, Pienkowski, T, Costa, M. Magalhães, Müller-Schimpfle, M, Lebovic, G.S, Schneebaum, S

Get full text

327PSurvival of HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine: A national population-based study: Long-term analysis by Jagielska, B, Tokajuk, P, Pieńkowski, T, Czubek, A, Krzakowski, M J, Wojtukiewicz, M Z

Get full text

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) by Zielinski, C.C, Lang, I, Inbar, M, Kahan, Z, Greil, R, Beslija, S, Stemmer, S.M, Zvirbule, Z, Steger, G.G, Melichar, B, Pienkowski, T, Sirbu, D, Petruzelka, L, Eniu, A, Nisenbaum, B, Dank, M, Anghel, R, Messinger, D, Brodowicz, T

Get full text

Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines by Pieńkowski, T, Jagiello-Gruszfeld, A

“…Vinorelbine has proven to be effective in pretreated metastatic breast cancer patients. In particular, no cross-resistance with anthracyclines has been…”
Get more information

Randomised, phase II trial comparing oral capecitabine (Xeloda ) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines by TALBOT, D. C, MOISEYENKO, V, LAWS, S, OSTERWALDER, B, VAN BELLE, S, O'REILLY, S. M, CONEJO, E. Alba, ACKLAND, S, EISENBERG, P, MELNYCHUK, D, PIENKOWSKI, T, BURGER, H-U

“…Capecitabine, an oral fluoropyrimidine carbamate, was designed to generate 5-fluorouracil preferentially at the tumour site. This randomised, phase II trial…”
Get full text

50 Long Term Results and Prognostic Factors in Patients with Unicentric and Multicentric Breast Cancer by Galecki, J, Kolodziejczyk, M, Michalski, W, Pienkowski, T, Mentrak, Z, Towpik, E

Get full text

5130 POSTER Long Term Results and Prognostic Factors in Patients With Unicentric and Multicentric Breast Cancer by Galecki, J, Kolodziejczyk, M, Michalski, W, Pienkowski, T, Mentrak, Z, Towpik, E

Get full text

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant by Robertson, J F R, Howell, A, Gorbunova, V A, Watanabe, T, Pienkowski, T, Lichinitser, M R

“…There is a need for new endocrine agents that lack cross-resistance with currently available treatments to extend the endocrine treatment window and delay the…”
Get full text